Ironwood Pharmaceuticals is trading 5.31% down at $3.57 as of 9:56 a.m. ET on October 16, 2026; broader biotech weakness may be contributing, though no company-specific catalyst is confirmed.

  • XBI was down 2.06% in regular trading amid a broad rotation away from higher-risk growth stocks; this does not confirm the cause of Ironwood Pharmaceuticals’ larger decline.
  • Tammi Gaskins will become CEO on January 1, 2027; the announcement does not by itself establish a cause for the drop.